По вашему запросу найдено документов: 360

Страница 3 из 36

ОШИБКИ В ДИАГНОСТИКЕ И АТИПИЧНОЕ ТЕЧЕНИЕ ЛЕЙШМАНИОЗА with Professor M.M. Gafarov and with the diagnosis of cutaneous leishmaniasis was hospitalized in the 1st

, Qiagen, USA), and genotyped polymorphic markers in 14 differentially expressed chemokine genes (CCL2, CCL

THE ROLE OF THE IL2-IL21 RS6822844 POLYMORPHISM IN THE PREDISPOSITION TO THE ERYTHROCYTE

The structure of 5,5-bis(bromomethyl)-2-phenyl-1,3-dioxane was investigated by the methods of 1Н

НАПРАВЛЕНИЕ РЕАКЦИИ 6-МЕТИЛПИРИМИДИН-2,4(1Н,3Н)-ДИОНА С 2-ХЛОРМЕТИЛТИИРАНОМ: N1- ИЛИ N3-ТИЕТАНИЛПРОИЗВОДНОЕ?The reaction of 6-methylpyrimidine-2,41H,3H-dione with 2-chloromethylthiirane gave 6-methyl

Thymidylate synthase (ThS) is a target for antimetabolite antitumor drugs. Such drugs have been

ETIOPATHOGENETIC FEATURES OF THE FURUNCLE OF THE MAXILLOFACIAL REGION of genes determining the pathogenicity and antibiotic resistance of S. aureus pure culture, isolated

STRUCTURE AND CONFORMATIONAL ANALYSIS OF 5,5-BIS(BROMOMETHYL)-2-(4-METHOXYPHENYL)-1,3-DIOXANEThe structure of 5,5-bis(bromomethyl)-2-(4-methoxyphenyl)-1,3-dioxane has been studied by H-1 and C

,4-dioxane in the presence of alkali and phase-transfer catalyst to give mono- and bis(2-cyanoethoxy) and 2

SHITARA, K., OHTSU, A., ÖZGÜROĞLU, M., BANG, Y.J., DI BARTOLOMEO, M., MANDALÀ, M., RYU, M.H.., FORNARO, L., OLESIŃSKI, T., CAGLEVIC, C., CHUNG, H.C., MURO, K., GOEKKURT, E., MANSOOR, W., MCDERMOTT, R.S., SHACHAM-SHMUELI, E., CHEN, X., MAYO, C., KANG, S.P., FUCHS, C.S., LERZO, G., O'CONNOR, J.M., MENDEZ, G.A., LYNAM, J., TEBBUTT, N., WONG, M., STRICKLAND, A., KARAPETIS, C., GOLDSTEIN, D., VASEY, P., VAN LAETHEM, J.L., VAN CUTSEM, E., BERRY, S., VINCENT, M., MULLER, B., REY, F., ZAMBRANO, A., GUERRA, J., KROGH, M., BAEKSGAARD, L., YILMAZ, M., ELME, A., MAGI, A., AUVINEN, P., ALANKO, T., MOEHLER, M., KUNZMANN, V., SEUFFERLEIN, T., THUSS-PATIENCE, P., HOEHLER, T., HAAG, G., AL-BATRAN, S.E., CASTRO, H., LOPEZ, K., AGUILAR VASQUEZ, M., SANDOVAL, M., LAM, K.O., CUFFE, S., KELLY, C., GEVA, R., HUBERT, A., BENY, A., BRENNER, B., GIUSEPPE, A., FALCONE, A., MAIELLO, E., PASSALACQUA, R., MONTESARCHIO, V., HARA, H., CHIN, K., NISHINA, T., KOMATSU, Y., MACHIDA, N., HIRONAKA, S., SATOH, T., TAMURA, T., SUGIMOTO, N., CHO, H., OMURO, Y., KATO, K., GOTO, M., HYODO, I., YOSHIDA, K., BABA, H., ESAKI, T., FURUSE, J., WAN MOHAMMED, W.Z., HERNANDEZ HERNANDEZ, C., CASAS GARCIA, J., DOMINGUEZ ANDRADE, A., CLARKE, K., HJORTLAND, G., GLENJEN, N., KUBIATOWSKI, T., JACEK, J., WOJTUKIEWICZ, M., LAZAREV, S., LANCUKHAY, Y., AFANASAYEV, S., MOISEYENKO, V., KOSTOROV, V., PROTSENKO, S., SHIRINKIN, V., SAKAEVA, D., FADEEVA, N., YONG, W.P., ROBERTSON, B., NG, C.H.M., ROBERTSON, B., RAPAPORT, B., COHEN, G., DREOSTI, L., RUFF, P., JACOBS, C., LANDERS, G., SZPAK, W., ROH, S.Y., LEE, J., KIM, Y.H., ALSINA MAQUEDA, M., LONGO MUNOZ, F., CERVANTES AGUILAR, A., ARANDA AGUILAR, E., GARCIA ALFONSO, P., RIVERA, F., FELIU BATLE, J., PAZO CID, R., YEH, K.H., CHEN, J.S., CHAO, Y., YEN, C.J., KARA, O., YALCIN, S., HOCHHAUSER, D., CHAU, I., BENSON, A., SHANKARAN, V., SHAIB, W., PHILIP, P., SHARMA, V., SIEGEL, R., SUN, W., WAINBERG, Z., GEORGE, B., BULLOCK, A., MYRICK, S., FARUOL, J., LARSON, T., BECERRA, C., RATNAM, S., RICHARDS, D.A., RICHE, S.L (2018)
-response and integrated web-response system to receive either pembrolizumab 200 mg every 3 weeks for up to 2 years

Страница 3 из 36